Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

A global map of the Zika virus phosphoproteome reveals host-driven regulation of viral particle release and cytopathogenicity.

Created on 04 Sep 2026

Authors

Inessa Manuelyan, Anna M Schmoker, Boyd L Yount, Philip Eisenhauer, Judith I Keller, Clarissa Gold, Dante Terino, Christopher M Ziegler, Jeff Alexander, Edward Hutchinson, David Bhella, Christopher D Syme, Douglas G Widman, Mark T Heise, Ralph S Baric, Bryan A Ballif, Jason W Botten

Published in

PLoS pathogens. Volume 22. Issue 9. Pages e1014300. Epub Sep 03, 2026.

Abstract

Flaviviruses are enveloped, positive-strand RNA viruses that cause millions of infections in the human population annually. Although Zika virus (ZIKV) had been detected in humans as early as the 1950s, its reemergence in South America in 2015 resulted in a global health crisis. While flaviviruses encode 10 proteins that can be post-translationally modified by host enzymes, little is known regarding post-translational modifications (PTMs) of the flavivirus proteome. We used mass spectrometry to comprehensively identify host-driven PTMs on the ZIKV proteome. This approach allowed us to identify 43 PTMs across 8 ZIKV proteins, including several that are highly conserved within the Flavivirus genus. Notably, we found two phosphosites on the ZIKV envelope protein that are functionally important for viral propagation. Both appear to regulate viral particle release, while one also impacts ZIKV cytopathogenicity. Additionally, we discovered host kinases that interact with ZIKV proteins and determined that Bosutinib-an FDA-approved tyrosine kinase inhibitor that targets some of these host kinases-impairs ZIKV growth, in part by blocking phosphorylation of a tyrosine residue on the envelope protein. Thus, we have defined a high-resolution map of host-driven PTMs on ZIKV proteins as well as cellular interacting kinases, uncovered novel mechanisms of host driven-regulation of ZIKV particle release and cytopathogenicity, and identified an FDA-approved inhibitor of ZIKV growth.

PMID:
42691041
Bibliographic data and abstract were imported from PubMed on 04 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 12
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement